Company intelligence / Profile preview

CellCentric

Cambridge, Essex, United Kingdomcellcentric.com ↗

Ownership: Private
Employees: ~20
Development stage: Phase 2

Overview

Inobrodib has completed Phase I safety and pharmacokinetic evaluation as a monotherapy and is currently being evaluated in expansion cohorts and new drug combinations. The company released promising efficacy and safety data at the American Society of Hematology (ASH) Annual Meeting last year.

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

inobrodib

Partnerships

RA Capital

Beyond the preview

Go deeper on CellCentric.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CellCentric.

Explore the full profile